CLAIMS

1. A peptide consisting of the amino acid sequence KIQEILTQV according to SEQ ID No. 14, wherein said peptide binds to a molecule of the human major histocompatibility complex (MHC) class-I, and wherein said peptide is capable of stimulating CD8 T cells, when used in the treatment of cancer, wherein the cancer is neuronal or brain cancer.

2. The peptide according to claim 1, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

3. An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct presenting said antigen to said CTL for a period of time sufficient to activate said CTL in an antigen specific manner, wherein the antigen is a peptide according to claim 1 or 2.

4. An activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 3, that selectively recognises a cell which aberrantly expresses a peptide comprising the amino acid sequence given in claim 1 or 2.

5. An antibody that specifically binds to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen, wherein said antigen is the peptide according to claim 1 or 2.

6. The activated cytotoxic T lymphocyte according to claim 4 or the antibody according to claim 5 when used in the treatment of cancer, wherein the cancer is neuronal or brain cancer.

7. The peptide according to claim 1 or 2, the activated cytotoxic T lymphocyte according to claim 4 or the antibody according to claim 5 when used in the treatment of cancer,

wherein the cancer is neuronal or brain cancer, and wherein the peptide, the activated cytotoxic T lymphocyte or the antibody is administered as a vaccine.

8. The peptide according to claim 1 or 2, the activated cytotoxic T lymphocyte according to claim 4 or the antibody according to claim 5 when used to treat cancer, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, neuroblastoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors, tumors of the pineal parenchyma, ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin, glioblastoma, CNS cancer, and leukemia medulloblastoma.